The burden of schizophrenia remains high, with one in 100 people affected globally over a lifetime.
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Symptoms are disabling, with auditory hallucinations, delusions, lack of motivation, cognitive impairment, and functional deficits. Despite advances in our understanding of the biological underpinnings of the illness, cure remains elusive. Antipsychotic medications are the mainstay of pharmacological treatment, but selecting the optimal medication for the individual patient is a delicate balance between efficacy and physical side-effects.
People with schizophrenia die up to 18 years earlier than the general population, largely due to avertable cardiometabolic diseases, 2 with a standardised mortality ratio of more than 3. 3 The risks are multifactorial, and include a genetic predisposition for abnormal glucose, poor diet, sedentary behaviour, and, notably, metabolic adverse reactions to antipsychotic medications. 4 In The Lancet, Maximilian Huhn and colleagues 5 report a network meta-analysis of antipsychotic medications for the acute management of schizophrenia that includes 402 studies of 32 different antipsychotics with data for 53 463 participants (mean age 37·40 years [SD 5·96], 29 949 [56·02%] male and 23 514 [43·98%] female, mean illness duration 11·90 years [SD 5·19]). This is the largest and most comprehensive meta-analysis of antipsychotic medication for acute psychosis to date. The use of a network meta-analysis allows comparisons between agents that might not have been directly compared in clinical trials. Other strengths include consideration of the placebo response rate, study sample size, publication year, baseline severity, sponsorship, comparability of doses, and patient demographics, using both meta-regression and sensitivity analyses of excluding poorer-quality studies. None of these factors greatly altered outcomes.
Many of the results are unsurprising. Clozapine remains the most effective antipsychotic for acute psychotic symptoms; however, it is now reserved for patients with treatment-refractory schizophrenia. 6 Several commonly used second-generation antipsychotics, including However, G6PD deficiency is also a contraindication for use of tafenoquine, and because of its prolonged action, it might require more stringent restriction in those with relatively low G6PD levels. Demonstration of safety with tafenoquine might allow it to eventually replace primaquine as a single-dose anti-relapse therapy. For now, the report by Taylor and colleagues 5 offers a potential strategy for halving the length of therapy for eliminating hypnozoites, which is an incremental yet important advance in the treatment of vivax malaria. amisulpride, risperidone, and olanzapine, were among the most effective treatments for psychotic symptoms; however, the differences in efficacy between the antipsychotics were more gradual than discrete. The most interesting results related to adverse drug reactions. Among second-generation antipsychotics, olanzapine, quetiapine, risperidone, and paliperidone were associated with marked weight gain, which the authors rated as being of high certainty of evidence. Amisulpride, risperidone, and paliperidone were associated with elevation of prolactin concentrations, whereas ziprasidone, amisulpride, and sertindole were associated with QTc prolongation. Second-generation antipsychotics (except quetiapine) had relatively low frequencies of anticholinergic adverse drug reactions.
First-generation antipsychotics such as haloperidol and perphenazine were also effective for psychotic symptoms. Although high-potency first-generation antipsychotics might not be associated with weight gain, they led to higher rates of akathisia, raised prolactin, and parkinsonian symptoms. However, the strength and generalisability of the findings for firstgeneration antipsychotics might have been affected by a lower placebo response than that found in later trials of second-generation antipsychotics and the relatively small number of study participants.
Social functioning was also comparatively underresearched compared to other outcomes, possibly reflecting a focus on clinician-defined as opposed to participant-defined outcomes.
How should this information influence our choice of medications for managing acute psychotic episodes for people with schizophrenia? Antipsychotic medications are unequivocally more effective than placebo for treating acute psychotic episodes in schizophrenia. Moreover, antipsychotic use versus no treatment is associated with significant reduction in all-cause mortality. 7 However, there must be a balance between the need to treat psychotic symptoms and the need to protect patient's physical health. Increasingly, clinical practice guidelines recommend against using secondgeneration antipsychotics commonly associated with high frequencies of weight gain, such as olanzapine or quetiapine, as first-line agents. 8 More weight-neutral antipsychotics, such as amisulpride or aripiprazole, should be selected first. If medications with high weight gain potential are selected, then they might need to be switched to weight-neutral agents once symptoms are more stable.
The precise role of first-generation antipsychotics in practice is still unclear and merits further research, given the relatively small numbers and low placebo response in existing studies. As Huhn and colleagues 5 highlight, their research could be particularly relevant for lowincome and middle-income countries, where lowercost first-generation antipsychotics might be more commonly used.
Patient involvement in both research outcomes and treatment choice is also crucial, particularly given evidence that this improves subsequent adherence. 9 Prescribers should, therefore, partner with patients to assist them in making informed choices, balancing evidence for efficacy of treatments with potential adverse drug reactions.
Monitoring and evidence-based treatment of cardiometabolic adverse events also remains essential. 4 This approach should combine advice and support around exercise, diet, and medications, such as metformin. 10 Management of acute schizophrenia should not be limited to medications. For instance, strong evidence supports the beneficial effects of psychosocial treatments, such as family therapy, cognitive interventions, and community-based rehabilitation. 11 Huhn and colleagues 5 have provided crucial information to inform antipsychotic prescribing. It is now time for prescribers to partner with patients and use this information to balance the needs of the mind and the needs of the body. 1 Less has been articulated about how to deliver this goal. In many low-income and middleincome countries, health-care systems are inadequate and providers rely on patients' out-of-pocket payments. Those who are poor and sick cannot access care or avoid seeking care because they are unable to pay. This situation contributes to unacceptably high burdens of preventable diseases and deaths.
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Some countries, including Ethiopia and Rwanda, are undertaking reforms to upgrade health systems and develop sustainable financing towards UHC.
2-4 We propose four practical steps for governments to define their pathway to UHC and align stakeholders around these reforms.
First, governments should define a cost-effective package of essential health benefits available to all. This priority setting process should be transparent, inclusive, and evidence-based. Governments should politically commit to equitably deliver these services to the entire population, irrespective of their ability to pay. The initial benefits package should include affordable, quality primary care and prevention, including comprehensive care for women, children, and vulnerable populations. Benefits will be context specific, but must give priority to the most common and recurrent health needs. This package must be realistic and not promise people more than what is possible to deliver or finance.
Second, governments should develop investment plans for the physical and human infrastructure needed to deliver benefits. This plan should include training and retraining for a sufficient number of health workers and the construction of health facilities and hospitals with clean water and power, medical equipment, laboratories, and management and information systems. Governments must strengthen supply chains and planning to procure the types and amounts of drugs, vaccines, and equipment needed, and to reach remote areas. The investment plan must be based on evaluation and costing of the needs of every local district.
Third, governments should develop a national health financing system, such as insurance, to fund health service delivery. To be universal, the domestic financing
